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ABSTRACT:
R-(1)-Pulegone, a monoterpene ketone, is a potent hepatotoxin. The
present study was designed to evaluate whether the reduction of the
ring size in R-(1)-pulegone would affect its mode of metabolism and
its hepatotoxic potential. Metabolic fate of R-(1)-4-methyl-2-(1-
methylethylidene)-cyclopentanone (I) and 5-methyl-2-(1-methylethyli-
dene)-cyclopentanone (DL-camphorone; II) were examined in rats.
Compounds I and II were administered orally (250 mg/kg of b.wt./day)
to rats for 5 to 7 days. The following metabolites were isolated and
identified from the urine of rats dosed with I: 3-methyl-5-(1-
methylethylidene)-cyclopent-2-enone (Ie), Z-4-methyl-2-(1-hy-
droxymethylethylidene)-cyclopentanone (Ib), E-4-methyl-2-(1-
hydroxymethylethylidene)-cyclopentanone (Ia), 3-hydroxy-4-methyl-
2-(1-methylethylidene)-cyclopentanone (If), 4-hydroxy-4-methyl-2-(1-
methylethylidene)-cyclopentanone (Ic), and E-4-methyl-2-(1-
carboxyethylidene)-cyclopentanone (Id). Phenobarbital (PB)-induced
rat liver microsomes in the presence of NADPH transformed com-
pound I into metabolites, which were identified as Ia, Ib, Ic, Ie, and If.
The following urinary metabolites were isolated and identified from
compound II: 5-hydroxy-5-methyl-2-(1-methylethylidene)-cyclopen-
tanone (IIc), 5-hydroxy-5-methyl-2-(1-methylethyl)-cyclopentanone
(IIg), Z-5-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (IIb),
5-methyl-2-(1-hydroxymethylethyl)-cyclopentanone (IIf), E-5-methyl-
2-(1-hydroxymethylethylidene)-cyclopentanone (IIa), E-5-methyl-2-(1-
carboxyethylidene)-cyclopentanone (IId), and 5-methyl-2-(1-carboxy-
ethyl)-cyclopentanone (IIe). PB-induced rat liver microsomes in the
presence of NADPH were shown to transform compound II to IIa, IIb,
and IIc. Studies carried out in vitro demonstrated that hydroxylation at
the tertiary carbon atom or oxidation of the isopropylidene methyl
groups in II can be specifically blocked through structural modifica-
tions as seen in compounds 2,2-dimethyl-5-(1-methylethylidene)-
cyclopentanone (III) and 5-methyl-2-(1-ethyl-1-propylidene)-cyclo-
pentanone (IV). Similar observation was also made when
isopropylidene methyl groups in R-(1)-pulegone were replaced by
ethyl groups. Intraperitoneal administration of a single dose (250
mg/kg) of I and II to rats did not elicit hepatotoxicity as judged by
serum alanine aminotransaminase levels and liver microsomal drug
metabolizing enzyme activities.
R-(1)-Pulegone, a monoterpene ketone, a major constituent of
pennyroyal oil from Mentha pulegium is a potent hepatotoxin (Gordon
et al., 1982; Thorup et al., 1983; Moorthy et al., 1989a, 1991). This
hepatotoxin is extensively metabolized in the rat system, and some of
the reactive metabolites formed are mostly responsible for the ob-
served toxicity (Gordon et al., 1987; Madyastha and Moorthy, 1989;
McClanahan et al., 1989; Madyastha and Raj, 1990). Two major
pathways are involved in the biotransformation of R-(1)-pulegone
(Moorthy et al., 1989b; Madyastha and Raj, 1993). One of the major
pathways is initiated through the regiospecific hydroxylation of
R-(1)-pulegone to 9-hydroxypulegone, and this reaction is catalyzed
by the liver microsomal cytochrome P450 system (Gordon et al.,
1987; McClanahan et al., 1988; Madyastha and Moorthy, 1989;
Madyastha and Raj, 1990). The 9-hydroxypulegone spontaneously
cyclized intramolecularly to a hemiketal, followed by dehydration to
menthofuran, a bicyclic furanoterpene (Gordon et al., 1987; Madyas-
tha and Moorthy, 1989; McClanahan et al., 1989; Madyastha and Raj,
1990). In the other major pathway, R-(1)-pulegone is stereoselec-
tively hydroxylated at the C-5 position, which upon dehydration
yields piperitenone (Madyastha and Raj, 1991, 1993). Most of the
metabolites of R-(1)-pulegone are derived from these two common
intermediates, viz. menthofuran and piperitenone. Menthofuran upon
further metabolism yields an a,b-unsaturated-g-ketoaldehyde, a
highly reactive metabolite capable of covalently interacting with liver
proteins (McClanahan et al., 1989; Madyastha and Raj, 1992). It has
been estimated that menthofuran is responsible for nearly half of the
hepatotoxicity caused by R-(1)-pulegone (Thomassen et al., 1990). In
fact, it is known that furano compounds upon metabolism yield
strongly electrophilic metabolites that covalently interact with tissue
macromolecules causing cell injury (Boyd, 1982). It has also been
demonstrated earlier that piperitenone becomes biotransformed fur-
ther to 6,7-dehydromenthofuran and p-cresol, besides other minor
metabolites (Madyastha and Gaikwad, 1999). Both these metabolites
could also contribute to R-(1)-pulegone-mediated toxicity (Deichman
and Keplinger, 1958; Boyd, 1982; Thomson et al., 1994). This is
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supported by the observation that the hepatotoxic potential of R-(1)-
pulegone is reduced considerably when the C-5 hydroxylation path-
way involved in the formation of piperitenone from pulegone is
blocked through structural modification (Thulasiram et al., 2000).
Several compounds structurally similar or related to R-(1)-pule-
gone have been tested for their ability to elicit hepatotoxic effects, and
these studies have indicated that the a-isopropylidene ketone group of
pulegone is the necessary structural unit required for eliciting hepa-
totoxicity (Gordon et al., 1982). Any variation in this structural
requirement such as reduction of either the ketone group or the
isopropylidene double bond completely eliminates the hepatotoxic
response (Gordon et al., 1982). Isomerization of the double bond to
the alicyclic position, as in isopulegone, or combination of exocyclic
and endocyclic double bonds, as in piperitenone, decreases the toxic
potential (Gordon et al., 1982). It is also known that removal of the
isopropylidene unit eliminates hepatotoxicity, whereas removal of the
C-5 methyl group only decreases the toxic response (Gordon et al.,
1982). In fact, inversion of configuration of the C-5 methyl group in
R-(1)-pulegone markedly affects the hepatotoxic potential. Thus,
S-(2)-pulegone is significantly less hepatotoxic than its enantiomer,
R-(1)-pulegone (Gordon et al., 1982; Madyastha and Gaikwad,
1998). Recently, it has been demonstrated that the C-5 chiral center in
R-(1)-pulegone contributes substantially to R-(1)-pulegone-medi-
ated toxicity (Thulasiram et al., 2000). All these studies clearly
indicate that some of the structural features of R-(1)-pulegone are the
important determinants for its hepatotoxic response. However, it is not
known whether reduction of the ring size in R-(1)-pulegone would
affect its hepatotoxic potential. To explore this, metabolic studies with
R-(1)-4-methyl-2-(1-methylethylidene)-cyclopentanone (I) and 5-meth-
yl-2-(1-methylethylidene)-cyclopentanone (DL-camphorone, II) (Scheme
1) were undertaken both in vivo and in vitro. Compounds I and II
(Scheme 1) are structurally very similar and have the same functional
groups as in R-(1)-pulegone, except there is a reduction in the ring size.
The purpose of the present investigation was to find out whether the rat
system carries out the regiospecific oxidation of I and II to their allylic
alcohols where the hydroxyl and keto groups are syn to each other and,
if so, would they undergo intramolecular cyclization followed by dehy-
dration to their corresponding furano compounds in a manner analogous
to the formation of menthofuran (Gordon et al., 1987; McClanahan et al.,
1989; Madyastha and Raj, 1990) and 6,7-dehydromenthofuran (Madyas-
tha and Gaikwad, 1999) from R-(1)-pulegone and piperitenone, respec-
tively. This information not only provides new insight into the toxic
potential of compounds I and II, but also on their mode of metabolism.
In fact, very little is known about the metabolism of five-membered
cyclic ketones in the mammalian system. The present study describes the
isolation and characterization of several novel metabolites from the urine
of rats dosed with compounds I and II, and many of the metabolites
characterized appear to be unknown. Preliminary studies pertaining to the
hepatotoxic potential of compounds I and II are also presented.
Materials and Methods
Chemicals. Glucose 6-phosphate, glucose-6-phosphate dehydrogenase,
NADP1, methylcellulose, and Tris-HCl were supplied by Sigma Chemical (St.
Louis, MO). Phenobarbital (PB1) was a generous gift from IDPL (Hyderabad,
India).
Synthetic Methods. R-(1)-4-Methyl-2-(1-methylethylidene)-cyclopen-
tanone (I), 5-methyl-2-(1-methylethylidene)-cyclopentanone (DL-camphorone,
II), and 2,2-dimethyl-5-(1-methylethylidene)-cyclopentanone (III) were syn-
thesized as reported earlier (Gole, 1949), and were purified by column chro-
matography over neutral alumina using 1 to 5% ethyl acetate in hexane.
5-Methyl-2-(1-ethyl-1-propylidene)- cyclohexanone (V) was synthesized ac-
cording to the method of Black et al. (1956). The compound was purified by
column chromatography over neutral alumina using hexane as the eluting
solvent. The compound (V) had the following spectral characteristics. Infrared
(IR) spectrum (neat) indicated the presence of an enone (1685 and 1611 cm21).
PMR spectra (CDCl3) were: d 2.65 and 2.60 (2t, 2H, J 5 4.5 Hz, H-3), 1.7–2.4
(m, 9H, methylene protons) and 0.91–0.99 (m, 9H, methyl protons). 13C NMR
spectra (75 MHz, CDCl3) were: d 204.9 (C1), 151.05 (C2), 131.8 (C8), 51.4
(C6), 33.4 (C3), 32.2 (C5), 28.3 (C9), 26.7 (C11), 25.6 (C4), 21.8 (C7), 13.7
(C10), and 12.5 (C12). Mass spectra were: m/z 180 (M1), 165 (M1-CH3), 151
(M1-C2H5), and 109 (M1-C4H7O).
5-Methyl-2-(1-ethyl-1-propylidene)-cyclopentanone (IV) was synthesized
as follows: lithium diisopropylamide (17.9 mmol, in 40 ml anhydrous THF)
was taken in a round-bottomed flask (150 ml) maintained under argon. The
contents of the flask were cooled to 250°C and 2-methyl cyclopentanone (1.4
g, 15.6 mmol in 10 ml THF) was added at 250°C under argon. The resulting
mixture was stirred at 250°C to 236°C for 30 min. Then, a solution of
3-pentanone (1.86 g, 21.6 mmol) in 10 ml of THF was added dropwise, and the
mixture was stirred for 30 min at 236°C and overnight at room temperature.
After completion of the reaction, the contents were cooled and a cold saturated
ammonium chloride solution (;25 ml) was added, and the product was
extracted with ether (50 ml 3 3). The combined ether extracts were washed
with water, brine, dried over anhydrous sodium sulfate, and evaporated to a
colorless liquid (75% yield). The compound (IV) was purified by column
chromatography over neutral alumina using 1% ethyl acetate in hexane as the
eluent. The compound had the following spectral characteristics. IR spectrum
(neat) showed absorptions at 1693 and 1610 cm21 (conjugated carbonyl
group). PMR spectra (CDCl3) were: d 2.67 (2 d, 2H, J 5 1.96 Hz, C-3
methylene protons), 2.51 (m, 2H, C-4 methylene protons), 2.3 (m, 1H, C-5
methine proton), 2.12 (q, 4H, J 5 5.8 Hz and 6.0 Hz, C-8 and C-10 methylene
protons), 1.09 (d, 3H, J 5 5.4 Hz, C-6 methyl protons), 1.03 (t, 3H, J 5 6.2
Hz, C-9 methyl protons), and 1.0 (t, 3H, J 5 6.12 Hz, C-11 methyl protons).
13C NMR spectra (75 MHz, CDCl3) were: d 207.7 (C1), 157.9 (C2), 129.6
(C7), 45.0 (C5), 28.6 (C8), 28.5 (C3), 26.5 (C10), 24.0 (C4), 14.8 (C6), 13.1
(C9), and 11.6 (C11). Mass spectra were: m/z 166 (base peak, M1), 151
(M1-CH3), 137 (M1-C2H5), and 109 (M1-C3H5O).
Hydrogenation of Compounds Ic, Id, and If. The compound (5.0 mg) was
dissolved in dry methanol (0.5 ml), and a catalytic amount of palladium
charcoal was added. The mixture was stirred for 2 h at room temperature under
hydrogen atmosphere. The reaction mixture was then diluted with chloroform
and passed through a celite bed, concentrated, and subjected to column
chromatography over neutral alumina. The product was eluted using 1 to 5%
ethyl acetate in hexane. The purified product was subjected to various spectral
analyses.
Animals and Dosing. Adult male rats (Wistar strain, 180–200 g) were used
in these studies. For isolation of metabolites, the test compound (I or II, 250
mg/kg of b.wt./day) was administered to rats (n 5 20) once daily for 5 days in
case of compound I and 7 days in case of compound II by gastric intubation
as a suspension in 1 ml of 1% methylcellulose solution. Control rats (n 5 6)
1
Abbreviations used are: PB, phenobarbital; IR, infrared; PMR, proton mag-
netic resonance; THF, tetrahydrofuran; ALT, alanine aminotransferase; GC, gas
chromatography; MS, mass spectroscopy; TLC, thin-layer chromatography; Rf,
relative front; Rt, retention time; LRMS, low-resolution mass spectra; HRMS,
high-resolution mass spectra.
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received only the vehicle. In our earlier studies (Madyastha and Raj, 1993),
R-(1)-pulegone was administered orally to rats (250 mg/kg) to investigate the
nature of urinary metabolites. LD50 in rats for R-(1)-pulegone is 245 to 250
mg/kg (Moorthy et al., 1989a). Since we wanted to compare the toxic potential,
as well as mode of metabolism of compounds I and II with that of R-(1)-
pulegone, we used the same amount of test compounds (250 mg/kg) in all our
experiments. Control and experimental rats were housed separately in stainless
steel metabolism cages with free access to food and water (laboratory animal
food from Brooke Bond and Lipton, Bangalore, India). Urine was collected
daily in bottles maintained at 0° to 4°C.
To evaluate the hepatotoxic potential of compounds I and II, and compare
these values to R-(1)-pulegone-mediated toxicity, rats were treated with
R-(1)-4-methyl-2-(1-methylethylidene)-cyclopentanone (I, 250 mg/kg of
b.wt.) or 5-methyl-2-(1-methylethylidene)-cyclopentanone (II, 250 mg/kg of
b.wt.) or R-(1)-pulegone (250 mg/kg of b.wt.) as a suspension in coconut oil
(0.3 ml). Control rats received only vehicle. Treatments were carried out
intraperitoneally (i.p.). It has been noted earlier that i.p. administration of a
single dose of R-(1)-pulegone caused a significant change in the levels of liver
microsomal glucose-6-phosphatase, aminopyrine N-demethylase, and serum
alanine aminotransferase (ALT). However, when the same dosage was admin-
istered orally, the changes observed in these activities were comparatively less
pronounced (Moorthy et al., 1989a). Both control and experimental rats were
housed separately in cages with free access to food and water. Animals were
killed by cervical dislocation 24 h after administration of test compounds.
In pretreatment experiments, rats were pretreated with phenobarbital (in 0.3
ml of 0.9% NaCl solution, 80 mg/kg of b.wt./day) for 4 days prior to i.p.
administration of test compounds (I or II, 250 mg/kg of b.wt.). For ALT
determinations, rats were killed while under light ether anesthesia, and blood
was drawn from the heart by cardiac puncture.
PB-induced microsomes were prepared from livers of rats treated with PB
(80 mg/kg of b.wt./day) for 4 days. Rats were killed by cervical dislocation
24 h after the final dose, and the livers were perfused with ice-cold 0.15 M KCl
solution.
Extraction of Urinary Metabolites. Urine samples collected daily from
control and experimental rats were adjusted to pH 4 to 5 with 1 N HCl and
extracted three times with diethyl ether. The ether extracts from each day were
pooled, concentrated, and separated into acidic and neutral fractions, as re-
ported earlier (Madyastha and Raj, 1993).
Preparation of Microsomes. PB-induced rat liver microsomes were pre-
pared as reported earlier (Madyastha and Raj, 1992). Microsomal pellets were
suspended in Tris-HCl buffer (0.05 M, pH 7.8) containing 0.25 M sucrose and
20% glycerol (v/v), and were stored at 220°C. Protein was estimated by the
method of Lowry et al. (1951).
Enzyme Assays. Cytochrome P450 (Omura and Sato, 1964), serum ALT
(earlier referred as glutamate pyruvate transaminase) (Reitman and Frankel,
1957), glucose-6-phosphatase (Traiger and Plaa, 1971), and aminopyrine N-
demethylase (Werringloer, 1978) were determined according to the reported
methods.
Studies in Vitro. Microsomal protein (2 mg/ml) was incubated in the
presence of NADP1 (0.5 mM), glucose 6-phosphate (5.0 mM), glucose-6-
phosphate dehydrogenase (1 unit), MgCl2 (10 mM), test compounds (I–V, 2
mM, in 50 ml acetone), and Tris-HCl (0.01 M, pH 7.4) in a total volume of 5.0
ml. The reaction was initiated by the addition of an NADPH-generating system
and incubated aerobically in a rotary shaker for 30 min at 37°C. At the end of
the incubation period, the assay mixtures were cooled to 0° to 4°C, the protein
was precipitated by adding 2.0 ml each of saturated Ba(OH)2 and 0.25 M
ZnSO4 solution, and the mixture was centrifuged (3000g). The supernatant was
extracted with methylene chloride (20 ml 3 3), concentrated, and an aliquot
was subjected to GC and GC-MS analyses. For isolating the metabolites,
organic extracts of several assays were pooled and processed.
Binding studies were conducted in potassium phosphate buffer (50 mM, pH
7.4) with control and phenobarbital-induced rat liver microsomes (;3 mg/ml)
as reported earlier (Madyastha and Gaikwad, 1998).
Chromatographic Procedures. Thin-layer chromatography (TLC) was
carried out on silica gel-G coated plates (0.25 mm for analytical; 0.75 mm for
preparative) developed with either hexane-ethyl acetate (8:2, v/v, system I) or
hexane-ethyl acetate (7.5:2.5, v/v, system II) or chloroform-methanol (9.6:0.4,
v/v, system III) or ethyl acetate-methanol-acetic acid (96.5:3:0.5, v/v, system
IV). The compounds were visualized by spraying with 3% vanillin in 1%
methanolic sulfuric acid followed by heating at 100°C for 5 to 10 min.
GC analyses were conducted on a Shimadzu model 14A instrument
equipped with a hydrogen flame ionization detector and Shimadzu HR-1 wide
bore capillary column (15 m 3 0.5 mm diameter). Nitrogen was used as the
carrier gas at a flow rate of 30 ml/min. Initially, the column temperature was
maintained at 60°C for 10 min, after which it was raised by 5°C/min to 150°C
and maintained at 150°C for 5 min.
Spectra. IR spectra were recorded on Perkin-Elmer model 781 spectropho-
tometer. Proton and 13C NMR spectra were recorded on JEOL FT-300 MHz
spectrometer. Chemical shifts are reported in ppm, with respect to tetrameth-
ylsilane as the internal standard. MS analyses were performed on a JEOL-
JMX-DX 303 instrument attached with a JMA-DA-5000 data system.
Results
Effect of Compounds I, II, and R-(1)-pulegone on Hepatic
Microsomal Enzymes. A number of liver microsomal enzymes and
serum ALT levels were determined 24 h after the i.p. administration
of compounds I and II (250 mg/kg of b.wt.) to rats. The effects of
compounds I and II on the hepatic microsomal enzymes were com-
pared with the effects observed after a single dose of i.p. administra-
tion of R-(1)-pulegone (250 mg/kg of b.wt.), a known hepatotoxin.
These preliminary results are summarized in Table 1. Consistent with
the earlier reports (Gordon et al., 1982; Moorthy et al., 1989b, 1991),
it was noted that i.p. administration of a single dose of R-(1)-
pulegone to rats resulted in a marked decrease in microsomal cyto-
chrome P450, aminopyrine N-demethylase, and glucose-6-phospha-
tase activities (Table 1). However, these activities were not
significantly affected after the administration of a single dose of
compounds I and II. Even the increase in ALT levels was only
marginal. It was also noted that pretreatment of rats with PB for 4 days
prior to the administration of I and II (as described under Materials
and Methods) did not alter significantly the levels of hepatic micro-
somal enzymes, as well as ALT levels (data not shown).
TABLE 1
Effect of i.p. administration of a single dose of DL-camphorone (I, 250 mg/kg), compound II (250 mg/kg), and R-(1)-pulegone (250 mg/kg) on rat liver microsomal
enzymes and ALT 24 h after the treatment
Enzyme Activity Control* Compound I % ChangeOver Control Compound II
% Change
Over Control R-(1)-Pulegone
% Change
Over Control
Cytochrome P450 (nmol/mg protein) 0.86 6 0.01 0.80 6 0.03 7.0 (2) 0.76 6 0.02 11.6 (2) 0.47 6 0.04 45.30 (2)
Cytochrome b5 (nmol/mg protein) 0.61 6 0.02 0.69 6 0.05 13.1 (1) 0.59 6 0.03 3.3 (2) 0.55 6 0.03 9.8 (2)
Glucose 6-phosphatase (nmol pi/min/mg protein) 193.13 6 5.13 191.25 6 3.75 0.95 (2) 178.25 6 7.2 7.7 (2) 102.3 6 4.23 47 (2)
Aminopyrine N-demethylase (nmol HCHO/min/mg
protein)
7.5 6 0.15 7.25 6 0.36 3.33 (2) 6.6 6 0.58 12.0 (2) 3.81 6 0.25 49.2 (2)
ALT (units/ml) 29.34 6 1.25 29.58 6 1.4 0.008† (1) 38.66 6 1.5 0.32† (1) 412.5 6 17.5 13.06† (1)
* Animals treated with vehicle alone. Animals were killed 24 h after the administration of test compounds. Values represent means 6 S.D. of three independent experiments consisting of tissues
pooled from 6 rats. (2) indicates % decrease over control and (1) indicates % increase over control.
† Values represent number of fold change over control. Other details of the experiment are as described under Materials and Methods.
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Biotransformation of R-(1)-4-Methyl-2-(1-methylethylidene)-
cyclopentanone (I). Neutral metabolites. Examination of the neutral
fraction (0.76 g) by TLC (system I) showed the presence of five
metabolites (Rf 0.43, 0.2, 0.18, 0.15, and 0.12) that were absent in the
control urine extract. This fraction was subjected to column chroma-
tography over neutral alumina (20 g), and the metabolites were eluted
with hexane-ethyl acetate mixtures. Elution of the column with hex-
ane yielded a compound (Rf 0.59 system I, Rt 5.4 min) identified as
unmetabolized substrate (I) by comparing its GC retention time,
PMR, and mass spectra with that of authentic compound.
The metabolite corresponding to Rf 0.43 (system I; Rt 11.8 min) was
eluted from the column with hexane-ethyl acetate (9.8: 0.2, v/v). From the
spectral characteristics (Table 2), it was identified as 3-methyl-5-(1-
methylethylidene)-cyclopent-2-enone (Ie, Fig. 1A). Elution of the col-
umn with hexane-ethyl acetate (9:1, v/v) yielded two fractions, one
containing a compound with Rf 0.2 (system I; Rt 15.0 min) and the other
with Rf 0.18 (system I; Rt 15.9 min). These two metabolites were further
purified by preparative TLC (system I). Based on the spectral character-
istics (Table 2), the metabolites with Rf 0.2 and 0.18 were identified as
Z-4-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (Ib, Fig.
1A) and E-4-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (Ia,
Fig. 1A), respectively.
Further elution of the column with hexane-ethyl acetate (8.8:1.2,
v/v) gave two compounds with Rf 0.15 and 0.12 (system I). The
spectral data of these compounds are presented in Table 2. From the
spectral characteristics, the compounds with Rf 0.15 (Rt 15.9 min) and
0.12 (Rt 15.0 min) were identified as 3-hydroxy-4-methyl-2-(1-
methylethylidene)-cyclopentanone (If, Fig. 1A) and 4-hydroxy-4-
methyl-2-(1-methylethylidene)-cyclopentanone (Ic, Fig. 1A), respec-
tively. It was observed that the GC analysis of Ic (Rt 15.0 min) upon
storage indicated the appearance of a new peak (Rt 11.8 min), which
was enhanced when mixed with 3-methyl-5-(1-methylethylidene)-
cyclopent-2-enone (Ie, Fig. 1A).
Acidic metabolites. TLC examination (system IV) of the acidic
fraction showed the presence of one compound (Rf 0.51, Rt 19.9 min),
which was absent in control urine extract. This fraction (0.8 g) was
chromatographed on a silica gel column (30 g), and the compound
corresponding to Rf 0.51 was eluted with hexane-ethyl acetate (19:1,
v/v). From the spectral characteristics (Table 2), the compound was
tentatively identified as E-4-methyl-2-(1-carboxyethylidene)-cyclo-
pentanone (Id, Fig. 1A).
Composition of the total urine extract was determined by GC
analyses, which showed the presence of seven peaks corresponding to
metabolites and unmetabolized compound I. These peaks were en-
hanced when mixed with the purified metabolites (Ia–If) isolated by
column chromatography. GC profile also showed a couple of very
minor peaks, which accounted for 5% of the total metabolites formed,
and these minor metabolites could not be characterized. Nearly 35%
of the administered dose was excreted in the urine as metabolites and
FIG. 1. A, probable metabolic pathways of R-(1)-4-methyl-2-(1-
methylethylidene)-cyclopentanone (I); B, probable metabolic pathways of 5-
methyl-2-(1-methylethylidene)-cyclopentanone (II).
TABLE 2
Spectral data for metabolites derived from compound I
Compound IR (neat) gmax 1H NMR (d) CDCl3 MS (LRMS and HRMS)
Ia 3400 cm21 (OOH),
1703 and 1627 cm21
(conjugated carbonyl)
4.2 (s, 2H, HO9), 2.8 (d, 2H, J 5 10.8 Hz, HO3),
2.5 (2d, 2H, J 5 7.5 Hz, HO5), 2.27 (s, 4H,
HO8 and HO4), 1.1 (d, 3H, J 5 7.5 Hz, HO6)
m/z: 154 (M1, bp), 139 (M1OCH3), 136 (M1OH2O), 125
(M1OC2H5), 121 (M1OCH3OH2O), 111 (M1OCOOH2O)
HRMS: C9H14O2 requires 154.0994, found 154.0997
Ib 3400 cm21 (OOH),
1680 and 1610 cm21
(conjugated carbonyl)
4.3 (s, 2H, HO8), 2.2–2.6 (m, 5H, ring protons), 1.9
(s, 3H, HO9), 1.05 (d, 3H, J 5 6.0 Hz, HO6)
m/z: 154 (M1), 139 (M1OCH3), 136 (M1OH2O), 121
(M1OCH3OH2O)
HRMS: C9H14O2 requires 154.0994, found 154.0996
Ic 3440 cm21 (OOH),
1690 and 1629 cm21
(conjugated carbonyl)
2.6 (bs, 2H, HO3), 2.4 (s, 2H, HO5), 2.1 (s, 3H,
HO8), 1.77 (s, 3H, HO9) 1.38 (s, 3H, HO6)
m/z: 154 (M1), 139 (M1OCH3), 136 (M1OH2O), 121
(M1OCH3OH2O), 111 (M1OCOOCH3), 96 (M1OC3H6O)
HRMS: C9H14O2 requires 154.0994, found 154.1001
Id 3100 cm21 (carboxyl), 1706 and
1690 cm21 (carbonyl groups)
2.35 (s, 3H, HO8), 2.06–2.6 (m, 5H, ring protons),
1.11 (d, 3H, J 5 6.44 Hz, HO6)
m/z: 168 (M1), 150 (M1OH2O), 140 (M1OCO), 122
(M1OCOOH2O)
Ie 1695 and 1620 cm21
(conjugated carbonyl)
6.05 (s, 1H, HO2), 3.1 (s, 2H, HO4), 2.3 (s, 3H,
HO8), 2.1 (s, 3H, HO6), 1.86 (s, 3H, HO9)
m/z: 136 (M1, bp), 121 (M1OCH3), 93 (M1OCOOCH3)
HRMS: C9H12O requires 136.0888, found 136.0886
If 3390 cm21 (OOH), 1690 and
1620 cm21 (conjugated
carbonyl)
4.6 (s, 1H, HO3), 2.7 (2d, 2H, J 5 8.1 Hz, HO5),
2.3 (bs, 4H, HO8, and HO4), 2.04 (s, 3H,
HO9), 1.0 (d, 3H, J 5 6.9 Hz, HO6)
m/z: 154 (M1), 139 (M1OCH3), 136 (M1OH2O), 121
(M1OCH3OH2O), 111 (M1OCOOCH3), 83 (M1OC4H7O, bp)
HRMS: C9H14O2 requires 154.0994, found 154.0993
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unmetabolized substrate. However, these values are approximate,
since both substrate and metabolites are highly volatile and a consid-
erable amount must have been lost during extraction and storage.
Biotransformation of 5-methyl-2-(1-methylethylidene)-cyclopen-
tanone (II, DL-camphorone) in vivo. The neutral fraction (1.4 g) upon
TLC analysis (system II) revealed the presence of six compounds,
which were absent in the control urine extract. This fraction was
subjected to column chromatography over silica gel (30 g), and
elution of the column with hexane yielded a compound (Rf 0.76,
system II) identified as unmetabolized camphorone (II) by comparing
its PMR, IR, and mass spectra with that of authentic compound.
Elution of the column with hexane-ethyl acetate (9.8:0.2, v/v)
yielded two fractions, each containing mainly one compound and they
(Rf 0.35, 0.34, system II) were further purified by preparative TLC
(system II). The compound with Rf 0.35 showed a UV absorption
maximum at 255 nm. Based on the spectral characteristics (Table 3),
these two metabolites were identified as 5-hydroxy-5-methyl-2-(1-
methylethylidene)-cyclopentanone (Rf 0.35, Rt 9.1 min, IIc, Fig. 1B)
and 5-hydroxy-5-methyl-2-(1-methylethyl)-cyclopentanone (Rf 0.34,
Rt 5.3 min, IIg, Fig. 1B). Hydrogenation of IIc in the presence of
palladium charcoal resulted in the formation of IIg, as judged by
various spectral analyses.
The compounds with Rf 0.27 and 0.21 (system II) were eluted from
the column with hexane-ethyl acetate (9.6:0.4, v/v). The compound
with Rf 0.27 showed a UV absorption maximum at 257 nm. From the
spectral data (Table 3), these two metabolites were identified as
Z-5-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (Rf 0.27,
Rt 15.7 min, IIb, Fig. 1B) and 5-methyl-2-(1-hydroxymethylethyl)-
cyclopentanone (Rf 0.21, Rt 12 min IIf, Fig. 1B).
Additional elution of the column with hexane-ethyl acetate (9.6:0.4,
v/v) yielded a compound with Rf 0.2 (system II) and Rt 18.6 min. This
compound showed an UV absorption maximum at 250 nm. From the
spectral data (Table 3), the metabolite was identified as E-5-methyl-
2-(1-hydroxymethylethylidene)-cyclopentanone (IIa, Fig. 1B). Hy-
drogenation of IIa and IIb using palladium charcoal as catalyst
yielded the same product whose spectral characteristics (PMR and
MS) matched well with that of metabolite IIf (Fig. 1B). This obser-
vation further supports the structures assigned for IIa and IIb (Fig.
1B).
Acidic metabolites. Examination of the acidic fraction by TLC
showed two compounds (Rf 0.6 and 0.62, system IV), which were
absent in the control urine extract. These two compounds with Rf 0.6
(Rt 20.7 min) and Rf 0.61 (Rt 19.3 min) were eluted from the column
with 9.7:0.3 and 9.6:0.4 hexane-ethyl acetate (v/v), respectively. The
compounds were further purified by preparative TLC (system IV), and
their spectral data are presented in Table 3. Based on the spectral
characteristics, they were identified as E-5-methyl-2-(1-carboxyeth-
ylidene)-cyclopentanone (Rf 0.6, IId, Fig. 1B) and 5-methyl-2-(1-
carboxyethyl)-cyclopentanone (Rf 0.61, IIe, Fig. 1B). Hydrogenation
of IId in the presence of palladium charcoal as catalyst yielded a
product with spectral characteristics (PMR and MS), the same as that
of metabolite IIe.
GC analyses of the total urine extract showed the presence of seven
peaks corresponding to the metabolites (IIa–IIg). The peaks corre-
sponding to these metabolites were enhanced when mixed with the
purified metabolites isolated by column chromatography. GC profile
also showed couple of very minor peaks, which accounted for 9.4% of
the total metabolites formed. Nearly 37% of the administered dose
was excreted in the urine as metabolites and unmetabolized substrate.
These values may not be accurate, since both substrate and its me-
tabolites are highly volatile and a considerable amount must have
been lost during extraction.
Binding studies. Both compounds I and II elicit type I binding
spectrum (lmax 385–388 nm, lmin 420–423 nm), with control and
PB-induced microsomes. The value of spectral dissociation constant
(Ks) calculated from the double-reciprocal plot (as described under
Materials and Methods) for compound I with control and PB-induced
microsomes was 90.9 mM and 35.7 mM, respectively, and for com-
pound II was 55.5 mM and 29 mM, respectively. Binding affinity of
both compounds I and II toward PB-induced microsomes is compar-
atively higher than with control microsomes.
Biotransformation of compounds I and II by rat liver microsomes.
Phenobarbital-induced rat liver microsomes were incubated aerobi-
cally with R-(1)-4-methyl-2-(1-methylethylidene)-cyclopentanone
TABLE 3
Spectral data for metabolites derived from compound II
Compound IR (neat) gmax 1H NMR (d) CDCl3 MS (LRMS and HRMS)
IIa 3380 cm21 (OOH),
1690 and 1615 cm21
(conjugated carbonyl)
4.2 (s, 2H, HO9), 2.27 (s, 3H, HO8), 2.15 (m,
1H, exchanges with D2O), 1.95–2.7 (m, 5H, ring
protons), 1.1 (d, 3H, J 5 7.7 Hz, HO6)
m/z: 154 (M1), 136 (M1OH2O), 125 (M1OC2H5), 121
(M1OCH3OH2O), 111 (M1OCOOCH3), 83 (M1OC4H7O)
HRMS: C9H14O2 requires 154.0994, found 154.0994
IIb 3400 cm21 (OOH), 1680
and 1610 cm21
(conjugated carbonyl)
4.3 (s, 2H, HO8), 2.2–2.6 (m, 5H, ring protons),
1.9 (s, 3H, HO9), 1.05 (d, 3H, J 5 6.4 Hz,
HO6)
m/z: 154 (M1, bp), 139 (M1OCH3), 136 (M1OH2O), 125
(M1OC2H5), 121 (M1OCH3OH2O), 111 (M1OCOOCH3), 84
(M1OC4H6O)
HRMS: C9H14O2 requires 154.0994, found 154.0997
IIc 3440 cm21 (OOH), 1700
and 1610 cm21
(conjugated carbonyl)
2.8 (s, 1H, exchanges with D2O), 2.25 (s, 3H,
HO8), 1.87 (s, 3H, HO9), 1.9–2.5 (m, 4H,
HO3 & HO4), 1.23 (s, 3H, HO6)
m/z: 154 (M1), 139 (M1OCH3), 136 (M1OH2O), 126
(M1OCO), 121 (M1OCH3OH2O), 111 (M1OCOOCH3), 93
(M1OCOOH2OOCH3)
HRMS: C9H14O2 requires 154.0994, found 154.1007
IId 3000 cm21 (carboxyl), 1700
and 1670 cm21 (carbonyl
groups)
8.5 (bs, 1H, acidic proton), 2.32 (s, 3H, HO8),
2.2–3.1 (m, 5H, ring protons), 1.15 (d, 3H, J 5
6.6 Hz, HO6)
m/z: 168 (M1), 150 (M1OH2O), 140 (M1OCO), 123
(M1OCOOH), 98 (M1OC4H6O)
HRMS: C9H12O3 requires 168.0786, found 168.0771
IIe 3120 cm21 (carboxyl), 1720
and 1690 cm21 (carbonyl
groups)
6.7 (bs, 1H, acidic proton), 1.7–3.2 (m, 7H, HO2,
HO3, HO4, HO5, and HO7), 1.1 (d, 6H, J 5
6.4 Hz, HO6 and HO8)
m/z: 170 (M1), 152 (M1OH2O), 142 (M1OCO), 125
(M1OCOOH), 98 (M1OC3H4O2)
HRMS: C9H14O3 requires 170.0943, found 170.0954
IIf 3390 cm21 (OOH), 1720
cm21 (carbonyl)
3.6 (m, 2H, HO8), 1.8–2.6 (m, 7H, HO2, HO3,
HO4, HO5, HO7), 1.1 (d, 3H, J 5 6.4 Hz,
HO6), 0.95 (d, 3H, J 5 7.7 Hz, HO9)
m/z: 156 (M1), 141 (M1OCH3), 125 (M1OCH3O), 113
(M1OC2H3O), 98 (M1OC3H6O, bp)
HRMS: C9H16O2 requires 156.1150, found 156.1148
IIg 3440 cm21 (OOH), 1740
cm21 (carbonyl)
1.6–2.6 (m, 6H, HO2, HO3, HO4, and HO7),
1.2 (s, 3H, HO6), 0.95 (2d, 6H, J 5 7.7 Hz,
HO8 and HO9)
m/z: 156 (M1), 139 (M1OOH), 128 (M1OCO), 58
(M1OC6H10O)
HRMS: C9H16O2 requires 156.1150, found 156.1136
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(I) and 5-methyl-2-(1-methylethylidene)-cyclopentanone (DL-cam-
phorone, II) in the presence of NADPH as described under Materials
and Methods.
Transformation of I. TLC (system I) and GC analyses of the
methylene chloride extract of the assay mixture indicated the presence
of five metabolites (Ia, Ib, Ic, Id, and Ie). The peaks corresponding
to these metabolites were enhanced when admixed with samples
isolated from the urine of rats treated with compound I. GC-MS
analysis of the methylene chloride extract also revealed the presence
of five metabolites whose fragmentation pattern matched well with
that of Ia, Ib, Ic, Id, and Ie, isolated and characterized from the urine
extract. It was observed that PB-induced liver microsomes convert
nearly 21% of the added substrate (I) into these five metabolites (Ia,
Ib, Ic, Id, and Ie), whereas control microsomes were shown to
transform only 5% of added substrate (I) into these metabolites.
Transformation of II. The methylene chloride extract of the assay
mixture upon TLC (system I) and GC analyses indicated the presence
of three metabolites that corresponded well with IIa, IIb, and IIc. All
of the peaks corresponding to these metabolites were enhanced when
mixed with samples isolated from the urine extract. GC-MS analysis
of the methylene chloride extract of the reaction mixture indicated the
presence of three compounds whose fragmentation pattern matched
well with that of IIa, IIb, and IIc isolated from the urine of rats dosed
with II. It was demonstrated that PB-induced rat liver microsomes
convert nearly 16% of the substrate (II) to various metabolites (IIa,
IIb, and IIc) under the assay condition used, whereas uninduced
microsomes (control) transform only 4% of the substrate (II) into IIa,
IIb, and IIc.
Biotransformation of 2,2-dimethyl-5-(1-methylethylidene)-cyclo-
pentanone (III). PB-induced rat liver microsomes were incubated
aerobically with III in the presence of NADPH as described under
Materials and Methods. The methylene chloride extract of the assay
mixture upon TLC (system II) and GC analyses indicated the presence
of three metabolites (Rf 0.38, 0.35 and 0.34, system II) which were
absent in control experiment. The organic extract (60 mg) was sub-
jected to column chromatography on neutral alumina (6.0 g) and the
metabolites were eluted with hexane-ethyl acetate mixtures. Elution of
the column with hexane yielded a fraction containing unmetabolized
compound III (Rf 0.93 system II; Rt 5.7 min).
The metabolite with Rf 0.38 (Rt 16.8 min) was eluted from the
column with hexane-ethyl acetate (9.5:0.5, v/v) and from the spectral
data (Table 4), the compound was identified as 4-hydroxy-2,2-
dimethyl-5-(1-methylethylidene)-cyclopentanone (IIIa, Fig. 2A).
Further elution of the column with hexane-ethyl acetate (9.4:0.6, v/v)
yielded two fractions, each containing mainly one compound. These
two metabolites (Rf 0.35, 0.34) were further purified by preparative
TLC (system II). From their spectral data (Table 4), the metabolites
with Rf 0.35 (Rt 18.4 min) and Rf 0.34 (Rt 20.7 min) were identified
as Z-2,2-dimethyl-5-(1-hydroxymethylethylidene)-cyclopentanone
(IIIb, Fig. 2A) and E-2,2-dimethyl-5-(1-hydroxymethylethylidene)-
cyclopentanone (IIIc, Fig. 2A), respectively. It was noted that PB-
induced liver microsomes convert nearly 35% of the substrate (III)
into these three metabolites (IIIa, IIIb, and IIIc). However, the
percentage of conversion was significantly lower (;6%) when unin-
duced (control) rat liver microsomes were used.
Transformation of 5-methyl-2-(1-ethyl-1-propylidene)-cyclopen-
tanone (IV). Incubation of IV with PB-induced rat liver microsomes
in the presence of NADPH resulted in the formation of a metabolite
(Rf 0.44, system I, Rt 17.0 min), which was absent in the control
experiment. This metabolite was separated by column chromatogra-
phy on neutral alumina using hexane-ethyl acetate (9.4:0.6, v/v) as the
eluent. From the spectral data (Table 4), this metabolite was identified
as 5-hydroxy-5-methyl-2-(1-ethyl-1-propylidene)-cyclopentanone (IVa,
Fig. 2B). Nearly 16% of the substrate (IV) was converted into IVa.
However, the conversion was significantly less (4%) when uninduced
(control) rat liver microsomes were used.
Transformation of 2-(1-ethyl-1-propylidene)-5-methyl-cyclohex-
anone (V). PB-induced rat liver microsomes were incubated aerobi-
cally with compound (V) in the presence of NADPH as described in
Materials and Methods. The methylene chloride extract of the assay
mixture upon TLC (system I) and GC analyses showed the presence
of two metabolites (Rf 0.6 and 0.25 system I; Rt 12.3 min and 15.2
min, respectively) that were absent in the control experiment. This
fraction was subjected to column chromatography over neutral alu-
TABLE 4
Spectral data for metabolites derived from compounds III, IV, and V
Compound IR (neat) gmax 1H NMR (d) CDCl3 MS (LRMS and HRMS)
IIIa 3400 cm21 (OOH),
1690 and 1610 cm21
(conjugated carbonyl)
4.92 (d, 1H, J 5 6.0 Hz, HO4), 2.27 (s, 3H,
HO9), 2.03 (s, 3H, HO10), 1.79 (2d, 2H, J 5
2.1 Hz, HO3), 1.19 and 1.02 (2s, 6H, HO6 and
HO7)
m/z: 168 (M1), 153 (M1OCH3), 150 (M1OH2O), 135
(M1OCH3OH2O, bp), 107 (M1OCOOCH3OH2O)
HRMS: C10H16O2 requires 168.1150, found 168.1147
IIIb 3400 cm21 (OOH), 1690
and 1610 cm21
(conjugated carbonyl)
4.26 (s, 2H, HO9), 2.4 (t, 2H, J 5 7.2 Hz, HO4),
1.87 (s, 3H, HO10), 1.7 (t, 2H, J 5 7.5 Hz,
HO3), 1.02 (s, 6H, HO6 and HO7)
m/z: 168 (M1), 153 (M1OCH3), 150 (M1OH2O), 135
(M1OCH3OH2O, bp), 107 (M1OCOOCH3OH2O)
HRMS: C10H16O2 requires 168.1150, found 168.1157
IIIc 3400 cm21 (OOH), 1690
and 1613 cm21
(conjugated carbonyl)
4.15 (s, 2H, HO10), 2.46 (m, 2H, HO4), 2.22 (bs,
3H, HO9), 1.68 (t, 2H, J 5 7.8 Hz, HO3), 0.97
(s, 6H, HO6 and HO7)
m/z: 168 (M1), 153 (M1OCH3), 150 (M1OH2O), 135
(M1OCH3OH2O, bp) 125 (M1OCOOCH3), 107
(M1OCOOH2OOCH3)
HRMS: C10H16O2 requires 168.1150, found 168.1153
IVa 3400 cm21 (OOH), 1690
and 1605 cm21
(conjugated carbonyl)
2.71 (m, 2H, HO8), 2.49 (m, 2H, HO3), 2.18 (q,
2H, J 5 6.1 Hz, HO10), 1.95 (m, 2H, HO4),
1.23 (s, 3H, HO6), 1.07 (t, 3H, J 5 6.2 Hz,
HO9), 1.04 (t, 3H, J 5 6.04 Hz, HO11)
m/z: 182 (M1), 164 (M1OH2O), 149 (M1OCH3OH2O, bp), 121
(M1OCOOCH3OH2O)
HRMS: C11H18O2 requires 182.1307, found 182.1302
Va 3412 cm21 (OOH), 1678
and 1610 cm21
(conjugated carbonyl)
2.04–2.57 (m, 10H, methylene protons), 1.33 (s,
3H, HO7), 1.03 (q, 6H, J 5 7.5 Hz, HO10 and
HO12)
m/z: 192 (M1), 178 (M1OH2O), 163 (M1OCH3OH2O), 135
(M1OCOOCH3OH2O)
HRMS: C12H20O2 requires 196.1463, found 196.11462
Vb 1655 and 1610 cm21
(conjugated carbonyl)
5.88 (bs, 1H, HO2), 2.63 (t, 2H, J 5 6.3 Hz,
HO4), 2.42 (q, 2H, J 5 7.5 Hz, HO9), 2.29 (t,
2H, J 5 6.6 Hz, HO5), 2.17 (q, 2H, J 5 7.5
Hz, HO11), 1.93 (s, 3H, HO7), 1.07 (t, 3H, J
5 7.5 Hz, HO10), 1.03 (t, 3H, J 5 7.5 Hz,
HO12)
m/z: 178 (M1), 163 (M1OCH3), 149 (M1OC2H5), 96
(M1OC5H6O), 82 (M1OC7H12)
HRMS: C12H18O requires 178.1357, found 178.1343
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mina, and the metabolites were eluted with hexane-ethyl acetate
mixtures. Elution of the column with hexane yielded a fraction con-
taining the unmetabolized substrate (V, Rf 0.74, system I; Rt 7.2 min).
The metabolites with Rf 0.6 and 0.25 (system I) were eluted with
9.9:0.1, v/v and 9.4:0.6, v/v hexane-ethyl acetate, respectively. From
the spectral characteristics (Table 4), these metabolites were identified
as 6-(1-ethyl-1-propylidene)-3-methyl-2-cyclohexen-1-one (Rf 0.6, Rt
12.3 min; Vb, Fig. 2C) and 6-(1-ethyl-1-propylidene)-5-hydroxy-5-
methyl-cyclohexanone (Rf 0.25, Rt 15.2 min; Va, Fig. 2C). Nearly
8.5% of V was converted into these two metabolites.
Discussion
The objective of the present investigation was to find out whether
reduction in the ring size in R-(1)-pulegone would affect its hepato-
toxic potential and mode of metabolism. This aspect was evaluated
using R-(1)-4-methyl-2-(1-methylethylidene)-cyclopentanone (I) as
the test compound, which is structurally very similar to the potent
hepatotoxin, R-(1)-pulegone. Both the compounds (pulegone and
compound I) possess an a-isopropylidene ketone unit with a R-
configuration methyl group positioned b to the carbonyl group, a
characteristic structural feature of R-(1)-pulegone required for elic-
iting hepatotoxicity (Gordon et al., 1982). The only striking difference
between them is the size of the ring; pulegone is a cyclohexanone
derivative, whereas compound I is a cyclopentanone derivative. Com-
pound II is the positional isomer of I. The present study has demon-
strated that structural modification of R-(1)-pulegone by reducing the
ring size, as in I and II, eliminates its toxic potential. Studies carried
out with I and II, both in vivo and in vitro, clearly indicate the
existence of significant difference in the mode of biotransformation
between R-(1)-pulegone and compounds I and II. This difference in
the mode of biotransformation appears to be responsible for their (I
and II) inability to elicit hepatotoxicity.
The present study represents characterization of various metabolites
isolated from the urine of the rats dosed with I and II. We have
assigned chemical structures mainly by comparing the 1H-NMR spec-
tra of the metabolites with that of the substrates used. The structures
assigned were further confirmed by mass spectral analyses (LRMS
and HRMS). Most of the metabolites isolated and characterized ap-
pear to be hitherto unknown. It was not possible to accurately quantify
the metabolites formed due to their high volatility, although suitable
precautions were taken to minimize the loss and nonenzymatic trans-
formations of the metabolites during extraction and isolation. Specu-
lative pathways have been proposed for the biotransformation of I and
II (Fig. 1, A and B) on the basis of various metabolites isolated and
characterized. In fact, these hypothetical pathways are based more on
chemical logic than on direct experimental proof. However, studies
carried out in vitro using PB-induced rat liver microsomes supported
the in vivo findings and the proposed sequence of reactions.
It is interesting to note that the early sequence of reactions involved
in the biotransformation of I and II (Fig. 1, A and B) is similar to that
of R-(1)- and S-(2)-pulegone. The metabolic fate of R-(1)-pulegone
(Moorthy et al., 1989a; Madyastha and Raj, 1993) and its enantiomer
S-(2)-pulegone (Madyastha and Gaikwad, 1998) has been studied in
great detail. These studies have established that the methyl group syn
to the carbonyl in pulegone gets hydroxylated to 9-hydroxypulegone,
which on intramolecular cyclization followed by dehydration yields a
furanoterpene, menthofuran (Gordon et al., 1987; McClanahan et al.,
1988; Madyastha and Raj, 1990; Madyastha and Gaikwad, 1998). In
contrast, it was observed that both the isopropylidene methyl groups
(C-8 and C-9 methyls) in compounds I and II are hydroxylated
yielding Ia, Ib, IIa, and IIb (Fig. 1, A and B). In fact, in these
compounds (I and II), the methyl group syn to the carbonyl is poorly
hydroxylated. This observation is based on the fact that Ib and IIb are
the minor metabolites, whereas Ia and IIa are the major metabolites
(Fig. 1, A and B) isolated from the urine of rats treated with I and II,
respectively. Interestingly, unlike in the case of R-(1)- and S-(2)-
pulegone (Gordon et al., 1987; McClanahan et al., 1988; Madyastha
and Raj, 1990; Madyastha and Gaikwad, 1998), the metabolites Ib
and IIb do not undergo intramolecular cyclization to yield the corre-
sponding furano compounds. On the other hand, the major metabolites
Ia and IIa get further oxidized to the corresponding 9-carboxy deriv-
atives (Id and IId; Fig. 1, A and B). Earlier studies have established
that menthofuran, a furanoterpene, was one of the metabolites respon-
sible for at least half of the hepatocellular necrosis caused by R-(1)-
pulegone (Thomassen et al., 1988). Further metabolism of menthofu-
ran results in the formation of an a,b-unsaturated-g-ketoaldehyde
(McClanahan et al., 1988; Moorthy et al., 1989b; Madyastha and Raj,
1990) and p-cresol (Madyastha and Raj, 1991, 1993) as major me-
tabolites, the former binding irreversibly to the hepatic microsomal
fraction in vitro (McClanahan et al., 1989) and the latter a known
toxin, as well as a glutathione depletor (Thomassen et al., 1990). So,
it is quite possible that the inability of the rat system to produce
FIG. 2. Transformation of (A) 2,2-dimethyl-5-(1-methylethylidene)-
cyclopentanone (III), (B) 4-methyl-2-(1-ethyl-1-propylidene)-cyclopentanone (IV),
and (C) 5-methyl-2-(1-ethyl-1-propylidene)-cyclohexanone (V) by PB-induced rat
liver microsomes.
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furanoterpene from I and II could be one of the reasons for their
failure to elicit hepatotoxicity.
Earlier studies have also shown the hydroxylation of R-(1)- and
S-(2)-pulegone at the C-5 position (hydroxylation at the tertiary
carbon atom) to form 5-hydroxypulegone, which upon dehydration
yields piperitenone (Madyastha and Raj, 1993; Madyastha and Gaik-
wad, 1998). It is interesting to note that compounds I and II are also
hydroxylated at the tertiary carbon atom yielding Ic and IIc (4-
hydroxy and 5-hydroxy compounds; Fig. 1, A and B), respectively.
The 4-hydroxy compound (Ic) undergoes dehydration to form Ie, in a
manner analogous to the formation of piperitenone from 5-hydroxy-
pulegone. It appears that the keto group allylic to the C-5 methylene
protons in Ic facilitates the dehydration and formation of the C4-C5
double bond in Ie (Fig. 1A). Such a situation does not exist in IIc and
that may be the reason for its resistance to dehydration. On the other
hand, IIc gets converted to IIg (Fig. 1B) through reduction of the
isopropylidene double bond. In a similar way, reduction of the exo-
cyclic double bond in IIb and IId results in the formation of IIf and
IIe, respectively (Fig. 1B). Earlier, it was shown that reduction of the
isopropylidene double bond in pulegone eliminates its hepatotoxic
response (Gordon et al., 1982). Hence, it is reasonable to assume that
metabolites (Fig. 1B) IIe, Iif, and IIg may not elicit toxicity.
It can be inferred from the present study that the rat system initiates
the biotransformation of I and II either through hydroxylation at the
tertiary carbon atom or oxidation of the isopropylidene methyl groups
(C-8 and C-9 methyl groups). Studies carried out in vitro using
phenobarbital-induced rat liver microsomes in the presence of
NADPH and O2 support this observation and suggest direct hydroxy-
lation of I at the C-8, C-9, C-4, and C-3 positions (Fig. 1A). Com-
pound II gets hydroxylated at the C-8, C-9, and C-5 positions (Fig.
1B). GC analysis of the assays carried out in vitro indicated that the
levels of different metabolites formed from I and II were significantly
higher with phenobarbital-induced rat liver microsomes than with
uninduced liver microsomes, suggesting the involvement of the liver
microsomal cytochrome P450 system in the formation of these me-
tabolites. In fact, earlier it was demonstrated that the microsomal
cytochrome P450 system carries out the regiospecific oxidation of
R-(1)-pulegone to its allylic alcohol (Gordon et al., 1987; McClana-
han et al., 1988; Madyastha and Raj, 1990). It is interesting to note
that the hydroxylation at the tertiary carbon atom or oxidation of the
isopropylidene methyl groups in compounds I and II can be specifi-
cally blocked through structural modification. This is evident from our
studies carried out in vitro using compounds III and IV. When C-5
hydrogen in II is replaced by another methyl group as in 2,2-dimethyl-
5-(1-methylethylidene)-cyclopentanone (III), the phenobarbital-in-
duced rat liver microsomes transform III into metabolites, where the
isopropylidene methyl groups are oxidized (Fig. 2A). On the other
hand, when the allylic methyl groups in II are replaced by ethyl
groups as in 5-methyl-2-(1-ethyl-1-propylidene)-cyclopentanone
(IV), the microsomes carry out hydroxylation only at the tertiary
carbon atom to yield IVa. Earlier studies have demonstrated that
structural modification of R-(1)-pulegone by replacing the C-5 hy-
drogen with a methyl group has blocked one of the major metabolic
pathways of R-(1)-pulegone initiated through hydroxylation at the
C-5 position, although the rat system has retained its ability to carry
out allylic methyl hydroxylation (Thulasiram et al., 2000). Opposite of
this, phenobarbital-induced rat liver microsomes exclusively carry out
hydroxylation at the C-5 position (hydroxylation at the tertiary carbon
atom) when the isopropylidene methyl groups in R-(1)-pulegone are
replaced by ethyl groups as in 2-(1-ethyl-1-propylidene)-5-methyl-
cyclohexanone (V, Fig. 2C). The present and the earlier findings
(Thulasiram et al., 2000) indicate that it is possible to block the C-5
and C-9 hydroxylation pathways involved in the metabolism of
R-(1)-pulegone through structural modification. Both these pathways
generate toxic metabolites and hence blocking one of the pathways
would significantly reduce the hepatotoxic potential of the structurally
modified R-(1)-pulegone (Thulasiram et al., 2000).
In the present study, we have compared the hepatotoxic potential of
compounds I and II with R-(1)-pulegone, a potent hepatotoxin. These
preliminary studies point out that I and II are not hepatotoxic. This
observation is based on the fact that i.p. administration (250 mg/kg of
b.wt.) of I/II to rats did not significantly alter the levels of hepatic
microsomal cytochrome P450, aminopyrine N-demethylase, glucose-
6-phosphatase, and serum ALT (Table 1). Pretreatment of rats with
phenobarbital, prior to the administration of compounds I and II, did
not significantly change these parameters suggesting that these com-
pounds do not elicit toxicity (results are not presented). In fact, studies
carried out in vitro clearly indicate that phenobarbital-induced rat liver
microsomes transform I and II to various metabolites more efficiently
than uninduced microsomes. So, if any of these metabolites have the
ability to elicit toxicity, then one would expect to see significant
changes in the levels of glucose-6-phosphatase, aminopyrine N-de-
methylase, and ALT after the administration of I or II to rats pre-
treated with phenobarbital. Since the levels of microsomal enzymes
and ALT have not changed, it appears that the metabolism of I and II
does not result in the formation of reactive metabolites responsible for
eliciting toxicity. However, consistent with the earlier report (Moor-
thy et al., 1989a, 1991), R-(1)-pulegone caused severe hepatotoxicity
in rats, as evidenced by a significant increase in ALT levels (a 13-fold
increase, Table 1) and potentiation of hepatotoxicity when it was
administered to PB-treated rats (results not shown). Our results sug-
gest that the hepatotoxic potential of R-(1)-pulegone can be elimi-
nated by reducing the ring size as in I and II. This could be possibly
due to the differences in the mode of metabolism between R-(1)-
pulegone and compounds I and II.
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